A 58-year-old man with a 10-year history of type 2 diabetes and hypertension presents to the cardiology clinic for lipid management. His current medications include metformin, lisinopril, and amlodipine. Fasting lipid panel shows: total cholesterol 285 mg/dL, LDL-C 180 mg/dL, HDL-C 32 mg/dL, triglycerides 380 mg/dL. He is started on atorvastatin 40 mg daily. After 6 weeks, repeat lipids show: LDL-C 95 mg/dL (target achieved), but triglycerides remain 320 mg/dL. His liver function tests and creatine kinase are normal. Which drug should be added to further reduce cardiovascular risk in this patient?

Explanation

## Clinical Context This patient has metabolic syndrome with persistent hypertriglyceridemia despite adequate LDL-C lowering on statin monotherapy. The triglyceride level of 320 mg/dL (still elevated) combined with low HDL-C and diabetes represents significant residual cardiovascular risk. ## Rationale for Fenofibrate **Key Point:** Fibrates are the first-line agents for hypertriglyceridemia, particularly when triglycerides exceed 200 mg/dL and LDL-C is already at goal on statin therapy. Fenofibrate works by: - Activating PPAR-α (peroxisome proliferator-activated receptor alpha) - Increasing lipoprotein lipase activity → enhanced triglyceride clearance - Reducing VLDL production in the liver - Modestly raising HDL-C **High-Yield:** In patients with diabetes + hypertriglyceridemia + low HDL, fibrates reduce non-fatal MI and stroke (ACCORD Lipid trial demonstrated benefit of fenofibrate + simvastatin in this phenotype). ## Why Fenofibrate Is Superior Here | Feature | Fenofibrate | Ezetimibe | Bempedoic Acid | Inclisiran | |---------|-------------|-----------|----------------|------------| | **Primary target** | Triglycerides, VLDL | LDL-C only | Uric acid + LDL | LDL-C only | | **Effect on TG** | ↓↓ (40–50%) | Minimal | Minimal | None | | **Effect on HDL** | ↑ (10–15%) | Minimal | Minimal | None | | **Indication here** | Persistent HTG | Already controlled LDL | Not HTG-specific | Not HTG-specific | **Clinical Pearl:** Fibrates + statins increase myopathy risk (especially with renal impairment). This patient's normal creatinine (implied by normal kidney function) and normal CK make combination safe. Monitor CK and renal function at baseline and 6 weeks. **Mnemonic — FIBRATE effects:** **F**ibrosis (↓ in liver), **I**ncreases HDL, **B**urnout of triglycerides, **R**educes VLDL, **A**ctivates PPAR-α, **T**herapy for metabolic syndrome, **E**ffective in diabetes. ## Safety Considerations - Fenofibrate is contraindicated in severe renal disease (eGFR <30) — this patient appears suitable - Dose adjustment needed if eGFR 30–60 mL/min/1.73m² (use 145 mg on alternate days or lower dose) - Monitor for myositis (especially if combined with statin) - Avoid in primary biliary cirrhosis [cite:KD Tripathi 8e Ch 31]